BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Industry & Community · 18 Oct 2026
Samsung Biologics Clears the PolyPeptide Threshold: What the Tender Offer Result Means for Peptide API Supply Chains
Samsung Biologics has secured 87.88% of PolyPeptide Group shares — well above the two-thirds minimum — and opened a second acceptance period through 30 October, with the CHF 1.46 billion acquisition on track to close by end-November. For research procurement teams, the deal reshapes who controls a significant share of global peptide API capacity.
Read briefing →
Pharma & GLP-1
EMA's CHMP Backs Orforglipron for the EU: What the Non-Peptide GLP-1 Opinion Means for the Research Landscape
The EMA's Committee for Medicinal Products for Human Use issued a positive opinion on 15 October 2026 recommending EU marketing authorisation for Eli Lilly's orforglipron (Foundayo) — a non-peptide, small-molecule GLP-1 receptor agonist. The decision, pending a European Commission rubber-stamp expected within weeks, adds regulatory momentum to a drug that differs structurally from every peptide GLP-1 approved to date, with consequences for manufacturing, compounding policy, and research-supply…
17 Oct 2026
Reputational Risks
Black Mould, Falsified Records, and Import Alert 66-40: What FDA Inspection Reports Reveal About Chinese GLP-1 API Suppliers
FDA inspection reports obtained under FOIA reveal black mould on equipment, insect contamination, destruction of samples during inspection, and falsified documentation at two Chinese manufacturers of semaglutide and tirzepatide active pharmaceutical ingredients. Both firms — Chengdu Shengnuo Biopharm and Nanjing Chengong Pharmaceutical — have been placed on Import Alert 66-40, with direct implications for compounding pharmacy supply chains and research-procurement quality assurance.
16 Oct 2026
Reputational Risks
Supplement-Grade API in Injectable Vials: The Glutathione Contamination Cluster That Illuminates a Systemic Compounding Risk
At least four US compounding pharmacies have recalled injectable glutathione products since August 2026 after elevated endotoxin levels were traced to a supplement-grade active pharmaceutical ingredient. Dozens of people have been sickened across multiple states. For research-procurement professionals, the cluster illustrates the specific hazard of API provenance gaps that can affect any compounded peptide injectable — not only the compounds currently under regulatory scrutiny.
15 Oct 2026
Industry & Community
REX Peptide ETF Launches on Nasdaq: What the First Dedicated Peptide Equity Vehicle Signals About Sector Capital and Research-Supply Dynamics
REX Shares launched the REX Peptide ETF (PEPT) on Nasdaq on 14 October 2026, offering the first single-ticker vehicle tracking the full peptide value chain from drug developers to CDMOs. The launch provides research-procurement professionals with a useful map of where institutional capital sees durable demand — and which parts of the supply chain are considered investable.
14 Oct 2026
Industry & Community
Multiplexed LC-HRMS for Nine GLP-1 Receptor Agonists: What a New Validated Method Means for Peptide Quality Control in Research Labs
A validated multiplexed LC-HRMS method covering nine structurally diverse GLP-1 receptor agonists — including survodutide, tirzepatide, and three investigational Phase III compounds — has been published in the Journal of Chromatography A. For research-procurement teams, it signals a meaningful step forward in the analytical toolkit available for identity confirmation and purity profiling of peptide reference materials.
13 Oct 2026
Regulatory & Policy
One Amino Acid, Three High Stakes: What the Seventh Circuit's Pending Retatrutide Ruling Means for Exclusivity, Medicare Pricing, and Compounding Access
The US Court of Appeals for the Seventh Circuit heard oral argument on 24 September 2026 in Eli Lilly v. FDA over whether retatrutide is legally a biologic or a drug — a question that turns on how one counts a single amino acid. The ruling, not yet published, will shape whether the triple agonist carries 5 or 12 years of exclusivity, when Medicare can negotiate its price, and whether any compounding pathway can ever lawfully exist.
12 Oct 2026
Regulatory & Policy
FDA Career Scientists Formally Oppose Administration's Interim Peptide Dispensing Plan — and What the Internal Split Means for Research Procurement
FDA drug centre staff have publicly stated they will not recommend allowing temporary compounding of unapproved peptides, placing career scientists in direct opposition to a Trump administration plan reported on 7 October 2026. The institutional fault line now visible inside the agency has immediate implications for how quickly — and through which channel — restricted peptides could re-enter legitimate supply.
11 Oct 2026
Reputational Risks
The FDA's Enforcement Paradox: Warning Letters, Import Bans, and China Supply Chain Scrutiny as Deregulation Signals Grow
Even as the Trump administration signals a more permissive posture towards certain restricted peptides, FDA enforcement has simultaneously accelerated across three fronts: warning letters to online sellers, a criminal prosecution yielding a 70-month sentence, and import bans on Chinese peptide API manufacturers. Research procurement teams need to understand both currents.
10 Oct 2026
Regulatory & Policy
HHS Stopgap Plan for Restricted Peptides: What the Reported Enforcement-Discretion Proposal Means for Research Procurement
The Trump administration is reported to be crafting a stopgap that would allow certain previously restricted peptides to be sold temporarily through compounding pharmacies while formal rulemaking proceeds — a development with direct implications for research procurement, supply chain integrity, and the ongoing FDA enforcement posture on GLP-1 combination products.
09 Oct 2026
Pharma & GLP-1
Novo Nordisk Bets €1.165 Billion on Atomic-Layer Deposition to Convert Semaglutide Into a Once-Quarterly Injectable
Swedish biotech Nanexa has secured a global exclusive licence from Novo Nordisk worth up to €1.165 billion to apply its PharmaShell atomic-layer deposition platform to peptide programmes in obesity, type 2 diabetes and other cardiometabolic diseases. The deal targets monthly and quarterly dosing profiles, and is backed by preclinical semaglutide data released earlier in 2026.
08 Oct 2026
Research Pipeline
Thymosin Alpha-1: What 35 Countries of Clinical Use and a Lopsided PCAC Vote Mean for Research Access in 2026
Thymosin alpha-1 (Tα1) holds approved-drug status in more than 35 countries for hepatitis B and immune support in oncology, yet its US regulatory position remains unresolved — the FDA's own advisory committee voted 4–17 against 503A compounding inclusion in December 2024. This briefing maps the clinical evidence, the mechanism, and what the peptide's unusual regulatory position means for UK research procurement today.
07 Oct 2026